

## Venous Thromboembolism During Pregnancy

S Felis\*, B Marchese, I Gavini

Department of Obstetric and Gynecological Clinic, Hospital "San Martino" Genoa, Italy.

### \*Corresponding Author

Salvatore Felis, Department of Obstetric-Gynecology, IRCCS-San Martino Hospital, Genoa, Italy.

Submitted: 20 July 2023; Accepted: 28 July 2023; Published: 12 Aug 2023

**Citation:** Felis S, Marchese B, Gavini I (2023). Venous Thromboembolism During Pregnancy. *Med Clin Res*, 8(8), 01-14.

### Abstract

Venous thromboembolism (VTE) is a major cause of maternal morbidity and mortality during pregnancy or early after delivery and it remains a diagnostic and therapeutic challenge. The latest Confidential Enquiry into Maternal Deaths showed that VTE is now the third leading cause of direct maternal mortality, beside sepsis and hypertension. In particular the prevalence of VTE has been estimated to be 1 per 1000-2000 pregnancies. The risk of VTE is five times higher in a pregnant woman than in non-pregnant woman of similar age and postpartum VTE is more common than antepartum VTE. This review aimed to provide an update of whole current literature on VTE in pregnancy highlighting the most recent findings in diagnostic and therapeutic strategies, considering in detail risks and benefits of various techniques and drug classes, for both mother and fetus. Large trials of anticoagulants administration in pregnancy are lacking and recommendations are mainly based on case series and on expert opinions. Nonetheless, anticoagulants are believed to improve the outcome of pregnancy for women with current or previous VTE.


**Keywords:** Deep Vein Thrombosis, Pulmonary Embolism, Pregnancy Progresses

### Introduction

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the two components of a single disease called venous thromboembolism (VTE). Approximately 30% of apparently isolated cases of PE are associated with DVT, and in patients with symptoms of DVT, the frequency of silent pulmonary embolism ranges from 40 to 50% [1,2]. VTE during pregnancy remains the leading medical cause of maternal mortality in the developed world, with an incidence of 0.85 per 100,000 pregnancies, as reported in the latest UK report MBRRACE-UK-Saving Lives, Improving Mothers' Care 2017 [3].

### Pathogenesis

VTE complicates 1 in 1000 pregnancies [4] and has a frequency 10 times higher than in the non-pregnant population [5,6]. This is due to the hypercoagulable state characteristic of pregnancy, which begins at conception and persists for over 8 weeks after delivery. The Virchow's triad (Figure 1), characterized by hypercoagulability, vascular damage, and venous stasis, is amplified during pregnancy, resulting in a relative risk of 4.3 (95% confidence interval (CI), 3.5 to 5.2) for VTE in pregnant or postpartum women compared to non-pregnant women [3].



**Figure 1:** Virchow's triad in pregnancy.

### *Venous stasis*

As pregnancy progresses, there is an expansion of blood volume and an increase in maternal cardiac output. At term, uterine blood flow increases from 700 to 900 mL/min, which represents 10-12% of the maternal cardiac output. The gravid uterus compresses the inferior vena cava and other structures (e.g., ureter). This caval compression leads to venous stasis distal to the compression in the pelvis and lower limbs.

### *Hypercoagulability*

Pregnancy is associated with rapid turnover of platelets, coagulation, and fibrinolysis. Platelet count remains unchanged or seemingly reduced due to hemodilution. There is an increase in the concentrations of fibrinogen, factors V, VII, VIII, IX, X, XII and thrombin. In addition to these, additional factors may coexist, exposing the pregnant woman to a higher risk of thromboembolism, such as Factor V Leiden mutation (which causes increased resistance to Protein C), the G20210A mutation of the prothrombin gene, protein S and C deficiencies, and antithrombin III deficiency. Pregnancy can be defined, from a coagulative perspective, as a state of accelerated but compensated intravascular coagulation.

### *Vascular damage*

During placental separation, microvascular injuries occur, which can trigger a series of events responsible for the acceleration of coagulation activity. This prothrombotic activity accounts for the increased incidence of thromboembolic events in the postpartum period. Cesarean delivery carries an eight-fold increased risk of thromboembolic events compared to vaginal delivery.

Furthermore, the presence of inherited thrombophilia and anti-phospholipid syndrome, as well as a history of previous thrombosis, increase the risk of VTE during pregnancy and the postpartum period [7].

### **Risk Factors**

The risk of VTE increases by 2-6 times during pregnancy and approximately 20 times in the postpartum period, persisting for at least 12 weeks afterward, although most thromboembolic events occur within 3 weeks after delivery. This risk is increased in women who are:

- Over 35 years old,
- Obese,
- Have thrombophilic abnormalities,
- Have a history of previous VTE,
- Undergo cesarean section (especially emergency cesarean section during labor) [7-9].

Most thromboembolic events occur during pregnancy, with an equal distribution across the three trimesters.

DVTs account for 75-80% of prenatal thromboembolism. Unlike non-pregnant women, DVTs during pregnancy involve the iliofemoral veins, with the main site of thrombus localization being the popliteal-femoral region. Approximately 90% of DVTs during pregnancy affect the left lower limb, compared to 55% in non-pregnant women [10]. This difference reflects the course of the iliac artery, which crosses the internal iliac vein on the left side and explains why, during pregnancy, most DVTs are iliofemoral rather than femoropopliteal (72% vs. 9%) [11].



For the assessment of thromboembolic risk during pregnancy, a thorough personal and family medical history is of fundamental importance, aimed at identifying any previous thromboembolic events in the patient or her first-degree relatives. This helps determine the need for pharmacological antithrombotic prevention measures and the opportunity for further diagnostic investigation.

For the evaluation of thromboembolic risk during pregnancy, see Appendix 1.

## Diagnosis of Acute Vte during Pregnancy

The clinical diagnosis of VTE, which is already challenging in the general population, is even more complicated in pregnant women

due to the physiological changes that occur during pregnancy, which can mimic signs and symptoms of VTE itself (Figure 2).

Venous Thromboembolism	Clinical presentation
 <p style="text-align: center;"><b>PULMONARY EMBOLISM</b></p>	<ul style="list-style-type: none"> <li>➤ Shortness of breath</li> <li>➤ Heart palpitations</li> <li>➤ Chest pain</li> <li>➤ Hemoptysis</li> <li>➤ Cyanosis/refractory hypoxia in case of massive PE</li> <li>➤ Tachycardia</li> <li>➤ Tachypnea</li> <li>➤ Hypotension</li> <li>➤ Shock</li> <li>➤ +/- signs of DVT</li> </ul>
 <p style="text-align: center;"><b>DEEP VEIN THROMBOSIS</b></p>	<ul style="list-style-type: none"> <li>➤ Proximal localization</li> <li>➤ Tenderness in the calf with digital compression</li> <li>➤ Dependent edema</li> <li>➤ Increased calf circumference</li> <li>➤ Increased temperature</li> <li>➤ Lisker's sign: intense pain with tibial percussion</li> <li>➤ Homan's sign: force dorsiflexion of the calf evokes pain</li> </ul>

**Figure 2:** Clinical manifestations of PE and DVT in pregnancy.

Diagnostic clinical tests used in the general population, such as the Wells score [12], cannot be applied during pregnancy due to their low positive predictive value. In recent years, a specific scoring system for pregnancy, the LEFTt test, has been proposed as a predictive test for DVT. This test combines three variables:

- Symptoms reported in the left lower limb (L)
- Difference  $\geq 2$  cm in calf circumference (E)
- Onset of symptoms in the first trimester (Ft)

Further future studies are needed to prospectively validate this test and define its role in a diagnostic algorithm for DVT during pregnancy [13].

Diagnostic investigations, particularly for pulmonary embolism, involve radiation exposure to both the mother and fetus, raising concerns, mostly unfounded, about the effects of radiation on the fetus, resulting in delayed confirmation of a diagnosis.

### Diagnosis of deep vein thrombosis [14]

In case of signs and symptoms suggestive of DVT:

- Initiate therapy with LMWH
- Make lower limb Doppler ultrasound

If the Doppler ultrasound is negative and signs and symptoms are not highly suggestive of DVT:

- Therapy can be discontinued

If the Doppler ultrasound is negative but signs and symptoms are highly suggestive of DVT:

- Repeat Doppler ultrasound after one week
- Continue therapy with LMWH until a negative Doppler ultrasound is obtained

In cases of suspected iliac vein thrombosis, with pain in the entire limb and abdominal region, magnetic resonance venography should be performed.

### Diagnosis of pulmonary embolism [14]

In cases of suspected PE:

- Complete blood count, electrolytes, liver and kidney function tests

**D-Dimer:** Outside of pregnancy, D-Dimer testing is used in the diagnosis of VTE, with high sensitivity, moderate specificity, and a high negative predictive value [15]. During pregnancy, D-Dimer levels progressively increase, with elevated values at term and in the postpartum period in healthy women [16]. D-Dimer

levels are significantly increased in multiple pregnancies [17], following cesarean section, in major bleeding, and in conjunction with pre-eclampsia [18]. In pregnancy, a positive D-Dimer does not necessarily confirm the diagnosis of VTE; its role remains controversial. The guidelines of the European Society of Cardiology recommend D-Dimer testing, stating that normal levels exclude PE in pregnancy as in other patients, although it is unlikely to find levels within the normal range during pregnancy [19]. In contrast, the guidelines of the American Society of Thoracic Radiology recommend not using D-Dimer testing for the diagnosis of VTE in pregnancy [20].

**ECG:** The most common abnormalities observed are inverted T waves, the classic S1Q3T3 pattern, and right bundle branch block (18% during pregnancy and 4.2% in the postpartum period) [21].

• **ABG:** Only 10% of cases show PO<sub>2</sub> values below 60 mmHg, and only 2.9% have saturation below 90%. These results indicate a diagnostic role for ECG in women with suspected acute PE, while blood gas analysis has limited diagnostic value [22].

**Chest X-ray** (differential diagnosis with pneumonia, pneumothorax, ARDS): while the chest X-ray is normal in over half of pregnant women with confirmed PE [22], abnormal features caused by PE include atelectasis, effusion, focal opacities, and pulmonary edema [23]. The radiation dose from a chest X-ray to which the fetus is exposed at any stage of pregnancy is negligible (less than 0.01 mSv) [24,25].

**Lower limb Doppler ultrasound:** necessary in cases of suspected PE and if the pregnant woman has signs and symptoms suggestive of DVT. Given the higher incidence of isolated iliac vein thrombosis in pregnancy [26], an increased probability of false negatives has been observed using Doppler methodology. Therefore, while a

positive result is valuable, in the case of a negative result, Doppler ultrasound does not help exclude PE. If the Doppler ultrasound is:

• **Positive:** No further investigations are necessary as the anticoagulant therapy is the same.

• **Negative:** But with strong clinical suspicion: Perform ventilation-perfusion (V/Q) scan or pulmonary CT angiography (CTPA).

**V/Q scan versus CTPA:** The choice between these two diagnostic tests depends on local availability and the diagnostic protocol approved by individual centers. CTPA has potential advantages over V/Q scan [27,28] such as:

- o More readily available
- o Higher sensitivity and specificity
- o Lower fetal radiation exposure

With both techniques, the doses used are well below accepted thresholds for teratogenicity, fetal death, and fetal growth retardation. The main concern for the fetus is a minimal increased risk of childhood cancer.

While CTPA is associated with a low risk of radiation to the fetus, the maternal breast tissue receives a relatively high radiation dose (up to 20 mGy), resulting in an increased risk of breast cancer [29]. The estimated radiation dose for CTPA is 20 to 100 times higher than for V/Q scan.

A radiation dose of 10 mGy to the breast of a pregnant woman increases the risk of developing breast cancer by 13.6% [30].

#### Treatment of Acute Vte

In the presence of signs and symptoms suggestive of DVT or PE, it is mandatory to initiate therapy with LMWH until the diagnosis is confirmed or unless treatment is strongly contraindicated (Table 1).

Contraindications/Precuations For The Use Of Lmwh
Known bleeding disorder (e.g., hemophilia, Von Willebrand disease or acquired coagulopathy)
Active prenatal or postpartum bleeding
Women with a high risk of bleeding (e.g., placenta previa)
Severe thrombocytopenia (platelet count < 75 × 10 <sup>9</sup> /L)
Acute stroke within the past 4 weeks (hemorrhagic or ischemic)
Severe renal insufficiency (glomerula filtration rate < 30 mL/minute )
Severe liver insufficiency (prothrombin time above the normal range or known varices)
Uncontrolled hypertension (systolic blood pressure > 200 mmHg or diastolic blood pressure > 120 mmHg diastolica)

**Table 1:** Contraindications for the use of EBPM ( da Nelson-Piercy C, MacCallum P, Mackillop L. Green-top Guideline No. 37a - reducing the risk of venous thromboembolism during pregnancy and the puerperium. London, Royal College of Obstetricians and Gynaecologists, 2015).

If left DVT is untreated, 15-25% of patients may develop PE. PE during pregnancy can be fatal in 15% of patients, and in 66% of these cases, death occurs within 30 minutes of the thromboembolic event [31,32].

#### LMWH Therapy

Advantages of LMWH compared to UFH:

- Greater efficacy
- Lower risk of bleeding [33]
- Lower mortality
- Lower incidence of heparin-induced thrombocytopenia and

osteoporosis [34,35].  
 • Half-life of 4-6 hours

The therapeutic dose of LMWH should be titrated according to the woman's pre-pregnancy weight (Table 2).

EBPM	Daily Dosage	
	Prophylactic dosage	Therapeutic dosage
ENOXAPARIN	4000 U/die	100 U/Kg every 12 h
NADROPARIN	2859 U/die up to 70 Kg 3800 U/Kg >70 Kg	180 U/Kg every 24 h
DALTEPARIN	5000 U/24 h	200 U/Kg every 24 h

**Table 2:** Therapeutic dose of Enoxaparin, Nadroparin, and Dalteparin Italian Official Gazette (G.U.) August 6, 2016: AIFA Determination regarding the prescription of LMWH in pregnancy and bridging therapy (see Appendix 2).

During pregnancy, changes in volume distribution and glomerular filtration can affect the pharmacokinetics of LMWHs. If creatinine clearance is below 30 mL/minute, lower doses of LMWH should be administered [36].

There are no recommendations for monitoring anti-Xa activity during LMWH treatment [37,38] except in women with body weight <50 kg or >90 kg or with other concurrent factors (e.g., renal insufficiency or recurrent VTE) [39]; and platelet count monitoring is not necessary [40,41].

If a pregnant woman is considered at high risk of bleeding, anticoagulant therapy should be managed with intravenous UFH until the bleeding risk is resolved.

UFH has a shorter half-life compared to LMWHs, and its activity can be antagonized by protamine sulfate or chloride. If a woman develops a bleeding issue during LMWH therapy, treatment should be discontinued, and hematological consultation should be sought.


### UFH Therapy

Massive PE is a medical emergency that can present with shock, refractory hypoxemia, and/or right ventricular dysfunction. If cardiac arrest occurs, maternal resuscitation should begin following the principles of CAB (compressions, airway, breathing) and manual left uterine displacement should be performed. Perimortem cesarean section should be performed within 5 minutes if resuscitation is unsuccessful, and the pregnancy is beyond 20 weeks [42].

Intravenous UFH is the initial treatment in massive PE due to its rapid onset of action and because it can be more easily titrated if thrombolytic therapy is administered [43].

How to administer UFH44 (Figure 3):

- Loading dose of 80 IU/kg followed by
- Continuous intravenous infusion of 18 IU/kg/h
- If the patient has undergone thrombolysis, the loading dose can be omitted, and the continuous intravenous infusion of 18 IU/kg/h is continued.



**Figure 3:** Therapy and monitoring of UFH treatment.

Monitoring of aPTT during UFH treatment is technically problematic, especially in late pregnancy when there is apparent heparin resistance due to increased levels of fibrinogen and factor VIII, which influence aPTT [45,46]. This can result in excessively high levels of UFH and subsequent bleeding issues. Therefore, the involvement of a hematologist in managing pregnant women receiving UFH treatment is desirable. It may be helpful to determine the anti-Xa level as a measure of heparin dose.

In the case of potentially life-threatening massive PE with hemodynamic compromise (or ischemic complications of an extremity due to extensive iliofemoral venous thrombosis), thrombolytic therapy should be considered as anticoagulation alone will not reduce obstruction in the circulation [47]. A meta-analysis has shown that the use of thrombolytic agents for PE is more effective than heparin therapy in reducing clot burden and improving hemodynamics [48]. These studies, however, did not demonstrate any impact on long-term survival compared to conventional therapy with UFH or LMWH, and the thrombolytic agent did not prove to be superior to any other [48]. However, when Wan et al. limited their analysis to trials involving massive PE, they identified a significant reduction in recurrent PE or death from 19.0% with heparin alone to 9.4% with thrombolysis (OR 0.45, 95% CI 0.22-0.90) [48].

Protamine sulfate or chloride reverses the anti-IIa fraction of LMWH, but it does not completely reverse the anti-Xa effect; therefore, protamine cannot be used as an antagonist for LMWH [49].

#### **Protamine dosage:**

1 mg of protamine chloride or sulfate per 100 IU of LMWH, administered as a slow intravenous infusion, up to a maximum of 50 mg in 10 minutes.

#### **Therapeutic scheme:**

- Intravenous UFH administered for a few minutes: 1-1.5 mg of protamine chloride per 100 IU of heparin.
- Intravenous UFH administered for 30-60 minutes: 0.50-0.75 mg of protamine chloride per 100 IU of heparin.
- Intravenous UFH administered for 2 hours: 0.25-0.37 mg of protamine chloride per 100 IU of heparin.
- Continuous intravenous UFH infusion: 25-50 mg of protamine chloride immediately after discontinuation of the infusion, with the remaining dose calculated for continuous infusion over 8-16 hours [50].

#### **Role of elastic compression**

In the initial treatment of DVT, the affected leg should be elevated, and graduated compression elastic stockings should be applied to reduce edema. Randomized studies have shown that early ambulation with leg compression does not increase the risk of PE, does not cause embolus migration, and improves pain and edema more quickly compared to patients with limited mobility [51,52].

Thigh-high elastic compression stockings appear to prevent post-

phlebotic syndrome to a greater extent than compression exerted below the knee.

Indications for the use of graduated compression elastic stockings are:

- a) Hospitalized pregnant women in whom LMWH therapy is contraindicated.
- b) Post-cesarean section hospitalized women (also receiving LMWH prophylaxis) at particularly high risk of VTE (previous VTE, presence of more than three risk factors for VTE).
- c) Pregnant women with a history of VTE (currently undergoing LMWH treatment).
- d) Pregnant women undertaking journeys lasting more than 4 hours.

#### **Role of caval filters**

Consideration should be given to the use of a temporary inferior vena cava filter in the peripartum period for patients with iliac vein thrombosis to reduce the risk of PE or in patients with diagnosed DVT who have recurrent PE despite adequate anticoagulant therapy.

The long-term safety of inferior vena cava filters is uncertain; the main complications associated with inferior vena cava filters are migration, increased risk of caval and lower extremity DVT, and rarely, infection [53].

#### **Maintenance of Anticoagulant Therapy during Pregnancy**

LMWHs are the preferred drugs for the treatment of VTE in pregnancy. Anticoagulant therapy should be continued for at least six weeks after delivery, for a minimum total treatment duration of three months [14].

The rationale for recommending therapeutic doses of LMWH rather than prophylactic doses for the whole duration of pregnancy is based on the continuous risk of recurrent VTE during the gestational period, which is influenced by:

- Changes in the hemocoagulative profile,
- Reduced venous flow velocity,
- A higher incidence of isolated iliac vein DVT,
- At least 50% of patients will have a thrombophilia.

#### **Role of vitamin K antagonists**

The use of coumarins in pregnancy is limited to a few situations where heparin is considered unsuitable, such as in women with older generation mechanical heart valves who have an increased risk of thrombosis even during anticoagulant therapy with UFH or LMWH.

Coumarins cross the placenta, leading to:

- Fetal anticoagulation: fetal bleeding
- Spontaneous abortions: fetal death

They also have teratogenic effects:

- Risk of 5%
- Dose-related risk: risk reduced if <5 mg/day

---

• Between the 6th and 12th week, they can cause the appearance of the so-called "warfarin embryopathy," characterized by nasal hypoplasia, optic atrophy, varying degrees of mental retardation, microcephaly, microphthalmia.

The risk of embryopathy is minimized if coumarins are replaced with LMWH between the 6th and 12th week of gestation.

Coumarin therapy appears to be reasonably safe in the second and third trimesters of pregnancy. It is advisable to switch to the more manageable heparin therapy near delivery (4 weeks before the estimated due date) to reduce the risk of maternal or neonatal bleeding complications.

The administration of oral anticoagulants is absolutely compatible with breastfeeding, considering the minimal passage of coumarins into breast milk [54].

#### **Role of new oral anticoagulants**

Fondaparinux (a selective factor Xa inhibitor) is recommended in pregnancy as an alternative to LMWH when heparin-induced thrombocytopenia occurs or in case of allergy to heparin [55-57]. Fondaparinux has a long half-life (18 hours), so there should be a gap of 36-42 hours from the previous dose administered before a neuraxial block can be performed. Fondaparinux treatment is not recommended during breastfeeding.

There are no indications for the use of oral vitamin K antagonists (NOACs: rivaroxaban, apixaban, betrixaban and dabigatran) in pregnancy or postpartum as they are likely to cross the placenta and have potential direct fetal effects, so they should be avoided during the prenatal period [58].

#### **Anticoagulant Therapy during Labor and Delivery**

When VTE occurs at term pregnancy, the use of intravenous UFH should be considered because it is more manageable.

Pregnant women receiving LMWH should discontinue its administration in case of labor or vaginal bleeding.

If elective cesarean section or labor induction is planned, LMWH therapy should be stopped 24 hours before.

In case of labor induction or potential neuraxial block, UFH therapy:

- Should be discontinued 12 hours before if administered subcutaneously,
- Should be discontinued 6 hours before if administered intravenously [59].

If women receiving therapeutic doses of UFH experience spontaneous labor, aPTT monitoring is required. If a significantly prolonged aPTT is observed near delivery, the administration of protamine sulfate may be necessary to reduce the risk of bleeding.

When VTE occurs at term, the risk of recurrent thrombosis may increase if anticoagulant therapy is interrupted to allow for planned labor induction or cesarean section. The risk of recurrent VTE

is higher if the discontinuation occurred within 2 weeks of the initial thrombotic event [60]. The use of intravenous UFH, which is more easily manageable and minimizes the duration without anticoagulant therapy due to its short half-life, may be considered. However, as noted earlier, there are challenges in monitoring UFH in pregnancy using aPTT.

#### **Safety of neuraxial blocks in obstetrics**

The incidence of spinal hematoma in the obstetric population, with or without anticoagulant therapy, is unknown. Obstetric patients have a lower incidence of spinal hematoma compared to elderly patients [61,62].

The introduction of thromboprophylaxis and antiplatelet therapy in parturients raises concerns about the safety of neuraxial anesthesia. On the other hand, excluding the use of neuraxial techniques in parturients receiving prophylactic or therapeutic antithrombotic treatment not only lacks rationale but is also undesirable considering the well-known benefits of central blocks in obstetrics [63].

When a pregnant woman is on therapeutic LMWH treatment, neuraxial techniques should not be performed for at least 24 hours from the last dose of LMWH.

Strict adherence to time intervals for LMWH administration should be observed:

- Time 0: Performance of neuraxial technique with placement of an epidural catheter.
- At 12 hours: Prophylactic dose of LMWH may be administered, followed by the next dose at 24 hours from the previous one.
- Removal of the epidural catheter should occur at least 10-12 hours after the administration of a prophylactic dose of LMWH.
- After 6 hours from the removal of the epidural catheter, a dose of LMWH may be administered.
- Administration of LMWH twice daily or at therapeutic doses is incompatible with the placement and/or maintenance of an epidural catheter.

These recommendations are based on the observation that LMWH, in addition to its anticoagulant and antiplatelet activity, also has significant fibrinolytic activity, which contributes to its antithrombotic effect but can increase the risk of spinal bleeding (as it can lyse an already formed clot in an epidural arterial vessel that may have been damaged by puncture or an epidural catheter) [63].

This fibrinolytic effect is related to the release of Tissue Plasminogen Activator (t-PA) and becomes significant starting from the third day of LMWH administration. In fact, it is known that 50% of hematomas occur 3 days after the initiation of LMWH administration, typically about 12 hours after the removal of the epidural catheter. This is considered a particularly critical time (likely more dangerous than the catheter insertion itself) because the patient has already received 2-3 doses of LMWH, and thus, the drug concentration approaches steady-state conditions [64,65].

### Anticoagulant Therapy in the Postpartum Period

Anticoagulant therapy should be continued for the duration of pregnancy and at least 6 weeks after delivery, with a total treatment duration of 3 months. Both LMWH and coumarins can be used in the postpartum period. Warfarin after delivery should be avoided for at least the first five days, and longer in women with an increased risk of bleeding.

### Prevention of Post-Thrombotic Syndrome (PTS)

Post-thrombotic syndrome is characterized by leg edema, persistent chronic pain, cyanosis, telangiectasia, eczema, varicose veins, and, in severe cases, venous ulceration.

For the prevention of PTS, the use of graduated compression elastic stockings with a pressure of 30-40 mmHg is recommended for over 2 years after the acute event [66].

### References

1. Turkstra F, Kuijer PM, van Beek EJ, Brandjes DP, ten Cate JW, et al. (1997) Diagnostic utility of ultrasonography of leg veins in patients suspected of having pulmonary embolism. *Ann Intern Med* 126:775-781.
2. Meignan M, Rosso J, Gauthier H, Brunengo F, Claudel S, et al. (2000) Systematic lung scans reveal a high frequency of silent pulmonary embolism in patients with proximal deep venous thrombosis. *Arch Intern Med* 160:159-164.
3. MBRRACE-UK Saving Lives, Improving Mothers' Care -Lessons learned to inform maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2013-15 December 2017.
4. Andersen BS, Steffensen FH, Sorensen HT, et al. The cumulative incidence of venous thromboembolism during pregnancy and puerperium—an 11 year Danish population-based study of 63,300 pregnancies. *Acta Obstet Gynecol Scand* 1998; 77: 170–173.
5. Anderson FA Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, et al. (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. *Arch Intern Med* 151:933-938.
6. White RH (2003) The epidemiology of venous thromboembolism. *Circulation* 107:14-18.
7. James AH, Jamison MG, Brancizio LR, Myers MR (2006) Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality. *Am J Obstet Gynecol* 194:1311-1315.
8. Idem (1996) Venous thromboembolic disease in obstetrics and gynaecology: the Scottish experience. *Scott Med J* 41:83-86.
9. Larsen TB, Sørensen HT, Gislum M, Johnsen SP (2007) Maternal smoking, obesity, and risk of venous Thromboembolism during pregnancy and the puerperium: a population-based nested case-control study. *Thromb Res* 120:505-509.
10. Ginsberg JS, Brill-Edwards P, Burrows RF, Bona R, Prandoni P, et al. (1992) Venous thrombosis during pregnancy: leg and trimester of presentation. *Thromb Haemost* 67:519-520.
11. McColl MD, Ramsay JE, Tait RC, Walker ID, McCall F, et al. (1997) Risk factors for pregnancy associated venous thromboembolism. *Thromb Haemost* 78:1183-1188.
12. Bourjeily G, Paidas M, Khalil H, et al. (2010) Pulmonary embolism in pregnancy. *Lancet* 375:500-512.
13. Rodger MA, Le Gal G, Wells P, Baglin T, Aujesky D, et al. (2014) Clinical decision rules and D-Dimer in venous thromboembolism: current controversies and future research priorities. *Thromb Res* 134:763-768.
14. RCOG Thrombosis and Embolism during Pregnancy and the Puerperium, the Acute Management of (Green-top Guideline No. 37b). 2015.
15. Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, et al. (2003) Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. *N Eng J Med* 349:1227-1235.
16. Khalafallah AA, Morse M, Al-Barzan AM, Adams M, Dennis A, et al. (2012) D-Dimer levels at different stages of pregnancy in Australian women: a single centre study using two different immunoturbidimetric assays. *Thromb Res* 130:e171-177.
17. Yamada T, Kawaguchi S, Araki N, Takeda M, Nishida R, et al. (2013) Difference in the D-dimer rise between women with singleton and multifetal pregnancies. *Thromb Res* 131:493-496.
18. Francalanci I, Comeglio P, Liotta AA, Cellai AP, Fedi S, Parretti E, et al. D-Dimer in intra-uterine growth retardation and gestational hypertension. *Thromb Res* 1995;80:89–92.
19. Torbicki A, Perrier A, Konstantinides S, Agnelli G, Galiè N, et al. (2008) ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). *Eur Heart J* 29:2276-2315.
20. Leung AN, Bull TM, Jaeschke R, Lockwood CJ, Boiselle PM, et al. (2011) ATS/STR Committee on Pulmonary Embolism in Pregnancy. An official American Thoracic Society/Society of Thoracic Radiology clinical practice guideline: evaluation of suspected pulmonary embolism in pregnancy. *Am J Respir Crit Care Med* 184:1200-1208.
21. Rodger MA, Carrier M, Jones GN, Rasuli P, Raymond F, et al. (2000) Diagnostic value of arterial blood gas measurement in suspected pulmonary embolism. *Am J Respir Crit Care Med* 162:2105-2108.
22. Blanco-Molina A, Rota LL, Di Micco P, Brenner B, Trujillo-Santos J, et al. (2010) RIETE Investigators. Venous thromboembolism during pregnancy, postpartum or during contraceptive use. *Thromb Haemost* 103:306-311.
23. Fidler JL, Patz EF Jr, Ravin CE (1993) Cardiopulmonary complications of pregnancy: radiographic findings. *AJR Am J Roentgenol* 161:937-942.
24. Damilakis J, Perisinakis K, Prassopoulos P, Dimovasili E, Varveris H, et al. (2003) Conceptus radiation dose and risk from chest screen-film radiography. *Eur Radiol* 13:406-412.
25. Nguyen CP, Goodman LH (2012) Fetal risk in diagnostic radiology. *Semin Ultrasound CT MR* 33:4-10.
26. James AH, Tapson VF, Goldhaber SZ (2005) Thrombosis during pregnancy and the postpartum period. *Am J Obstet*



- Gynecol 193:216-219.
27. Bhargavan M, Sunshine JH, Hervey SL, Jha S, Vializ J, et al. (2009) The actual role of CT and ventilation-perfusion scanning in workup for suspected pulmonary embolism: evidence from hospitals. *AJR Am J Roentgenol* 193:1324-1332.
  28. Vinayakamoorthy V, Geary S, Ganatra R (2010) A United Kingdom based survey of clinical practice in the diagnosis of suspected pulmonary embolism. *Nucl Med Commun* 31:112-120.
  29. Hurwitz LM, Reiman RE, Yoshizumi TT, Goodman PC, Toncheva G, et al. (2007) Radiation dose from contemporary cardiothoracic multidetector CT protocols with an anthropomorphic female phantom: implications for cancer induction. *Radiology* 245:742-750.
  30. Remy-Jardin M, Remy J (1999) Spiral CT angiography of the pulmonary circulation. *Radiology* 212:615-636.
  31. Rutherford SE, Phelan JP (1991) Deep venous thrombosis and pulmonary embolism in pregnancy. *Obstet Gynecol Clin North Am* 18:345-3470.
  32. Gherman RB, Goodwin TM, Leung B, Byrne JD, Hethumumi et al. (1999) Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. *Obstet Gynecol* 94:730-734.
  33. Lennox C, Marr L (2013) Reproductive Health Programme, Healthcare Improvement Scotland. Scottish Confidential Audit of Severe Maternal Morbidity. 9th Annual Report. (Edinburgh/Glasgow): Healthcare Improvement Scotland; 2013.
  34. Greer IA, Nelson-Piercy C (2005) Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. *Blood* 106:401-407.
  35. Dahlman TC (1993) Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. *Am J Obstet Gynecol* 168:1265-1270.
  36. Blombäck M, Bremme K, Hellgren M, Lindberg H (1998) A pharmacokinetic study of dalteparin (Fragmin) during late pregnancy. *Blood Coagul Fibrinolysis* 9:343-350.
  37. Kitchen S, Iampietro R, Woolley AM, Preston FE (1999) Anti Xa monitoring during treatment with low molecular weight heparin or danaparoid: inter-assay variability. *Thromb Haemost* 82:1289-1293.
  38. Greer I, Hunt BJ (2005) Low molecular weight heparin in pregnancy: current issues. *Br J Haematol* 128:593-601.
  39. Nutescu EA, Spinler SA, Wittkowsky A, Dager WE (2009) Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. *Ann Pharmacother* 43:1064-1083.
  40. Watson H, Davidson S, Keeling D (2012) Haemostasis and Thrombosis Task Force of the British Committee for Standards in Haematology. Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition. *Br J Haematol* 159:528-540.
  41. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, et al. (2012) American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141 2 Suppl:e495S-530S.
  42. Royal College of Obstetricians and Gynaecologists (2011) Maternal Collapse in Pregnancy and the Puerperium. Green-top Guideline No. 56. London: RCOG; 2011.
  43. Scottish Intercollegiate Guidelines Network (SIGN) (2010) Prevention and management of venous thromboembolism. SIGN publication no. 122. Edinburgh: SIGN; 2010.
  44. Raschke RA, Gollhare B, Peirce JC (1996) The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. *Arch Intern Med* 156:1645-1649.
  45. Hyers TM, Hull RD, Weg JG (1995) Antithrombotic therapy for venous thromboembolic disease. *Chest* 108:335S-351S.
  46. Raschke RA, Guidry JR, Foley MR (2000) Apparent heparin resistance from elevated factor VIII during pregnancy. *Obstet Gynecol* 96:804-806.
  47. Jaff MR, McMurtry MS, Archer SL, Cushman M, Goldenberg N, et al. (2011) American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; American Heart Association Council on Peripheral Vascular Disease; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a scientific statement from the American Heart Association. *Circulation* 123:1788-1830.
  48. Wan S, Quinlan DJ, Agnelli G, Eikelboom JW (2004) Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. *Circulation* 110:744-749.
  49. Van Veen JJ, Maclean RM, Hampton KK, Laidlaw S, Kitchen S, et al. (2011) Protamine reversal of low molecular weight heparin: clinically effective? *Blood Coagul Fibrinolysis* 22:565-570.
  50. <https://antidoti.ospfe.it/antidoto/protamina/>
  51. Aschwanden M, Labs KH, Engel H, Schwob A, Jeanneret C, et al. (2001) Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism. *Thromb Haemost* 85:42-46.
  52. Trujillo-Santos J, Perea-Milla E, Jiménez-Puente A, Sánchez-Cantalejo E, del Toro J, et al. (2005) RIETE Investigators. Bed rest or ambulation in the initial treatment of patients with acute deep vein thrombosis or pulmonary embolism: findings from the RIETE registry. *Chest* 127:1631-1636.
  53. National Institute for Health and Clinical Excellence (2012) Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. NICE clinical guideline 144. Manchester: NICE; 2012.
  54. McLintock C1 (2014) Thromboembolism in pregnancy: challenges and controversies in the prevention of pregnancy-

- associated venous thromboembolism and management of anticoagulation in women with mechanical prosthetic heart valves. *Best Pract Res Clin Obstet Gynaecol* 28(4):519-536.
55. Hajj-Chahine J, Jayle C, Tomasi J, Corbi P (2010) Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia. *Interact Cardiovasc Thorac Surg* 11:679-681.
  56. Ciurzyński M, Jankowski K, Pietrzak B, Mazanowska N, Rzewuska E, et al. (2011) Use of fondaparinux in a pregnant woman with pulmonary embolism and heparin-induced thrombocytopenia. *Med Sci Monit* 17:CS56-CS59.
  57. Nagler M, Haslauer M, Wuillemin WA (2012) Fondaparinux-data on efficacy and safety in special situations. *Thromb Res* 129:407-417.
  58. Tang AW, Greer I (2013) A systematic review on the use of new anticoagulants in pregnancy. *Obstet Med* 6:64-71.
  59. Gogarten W, Vandermeulen E, Van Aken H, Kozek S, Llau JV, et al. (2010) European Society of Anaesthesiology. Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology. *Eur J Anaesthesiol* 27:999-1015.
  60. Büller HR, Gent M, Gallus AS, Ginsberg J, Prins MH, et al. (1997) Low-molecular-weight heparin in the treatment of patients with venous thromboembolism. *N Engl J Med* 337:657-662.
  61. Crawford JS (1985) Some maternal complications of epidural analgesia for labour. *Anaesthesia* 40:1219-1225.
  62. Moen V, Dahlgren N, Irestedt L (2004) Severe neurological complications after central neuraxial blockades in Sweden 1990-1999. *Anesthesiology* 101:950-959.
  63. [www.sigo.it/wp-content/uploads/2015/10/raccomandazioni-tromboembolismo1.pdf](http://www.sigo.it/wp-content/uploads/2015/10/raccomandazioni-tromboembolismo1.pdf)
  64. Gris JC, Neveu S, Tailland ML, Courtieu Ch, Marès P, et al. (1995) Use of a low-molecular weight heparin (enoxaparin) or of a phenormin-like substance (moroxydine chloride) in primary early recurrent abortions with an impaired fibrinolytic capacity. *Thromb Haemost* 73:362-367.
  65. Kirchmaier CM, Lindhoff-Last E, Ruebesam D, Scharrer I, Vitgh Z, et al. (1994) Regression of deep vein thrombosis by i.v. administration of a low molecular weight heparin. Results of a pilot study. *Thromb Res* 73:337-348.
  66. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, et al. (2008) Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). *Chest* 133(6 Suppl):454-545.

## APPENDIX 1: Evaluation of Thromboembolic Risk in Pregnancy

The risk factors are listed in Table 3.

PRE-EXISTING FACTORS	SCORE	PRE-EXISTING FACTORS	SCORE	PRE-EXISTING FACTORS	SCORE
Previous VTE (excluding single surgery related event)	4	Pre-eclampsia	1	Any surgery in pregnancy or in puerperium (except immediate perineum repair)	3
Previous VTE related to major surgery	3	PMA	1	Hyperemesis	3
Known high risk thrombophilia	3	Multiple pregnancy	1	Ovarian hyperstimulation syndrome	4
Comorbidities (cancer, heart failure, LES, nephrotic syndrome, DM 1 with neuropathy)	3	Cesarean section in labor	2	Immobility, dehydration	1
Family history of VTE unrelated to estrogen intake in a first-degree relative	1	Elective cesarean	1	Systemic infection	1
Known low-risk thrombophilia	1	Operative delivery	1		
Age > 35 y	1	Prolonged labor > 24h	1		
BMI > 30	1	EPP > 1000 ml or transfusion	1		
BMI > 40	2	Preterm birth < 37 w	1		
Parity < 3	1	Intrauterine death	1		
Smoke	1	Smoke	1		
Varicose vein	1				

If prenatal score > 4 consider first trimester thromboprophylaxis.

If prenatal score 3 consider thromboprophylaxis from 28 weeks.

If postnatal score > 2 consider thromboprophylaxis for 10 days.

If pre-natal hospitalization consider thromboprophylaxis.

If prolonged hospitalization (23 days) consider thromboprophylaxis.

High bleeding risk evaluate benefit/risk ratio.

**Table 3:** Risk factors for VTE in pregnancy ( da Nelson-Piercy C, MacCallum P, Mackillop L. Green-top Guideline No. 37a-Reducing the risk of venous thromboembolism during pregnancy and the puerperium. London, Royal College of Obstetricians and Gynaecologists, 2015).

Two significant pre-existing risk factors recognized for VTE in pregnancy are thrombophilia and a previous VTE.

Inherited thrombophilia increases the risk of pregnancy-associated VTE up to 34 times (Table 4) as reported by Robertson et al. in a systematic review from 2006 that included nine studies.

The most significant risk factors for VTE in pregnancy are:

### Previous Vte

- Without apparent risk factors

- Estrogen-related
- Related to concurrent risk factors
- Related to thrombophilia

### Thrombophilia

- Antithrombin III deficiency
- Protein C deficiency
- Protein S deficiency
- Factor V Leiden mutation
- Prothrombin G 20210A mutation

Risk factor	Prevalence	Odds ratio
AT III deficiency (<80%)	<0.1–0.6	5
Protein C deficiency (<75%)	0.2–0.3	5
Protein S deficiency (<65%)	<0.1–0.1	3
Factor V Leiden:		
Heterozygosity	2.0–7.0	9
Homozygosity	0.2–0.5	34
Prothrombin G 20210A mutation:		
Heterozygosity	2.0	7
Homozygosity	Rare	26

**Table 4:** Prevalence of congenital thrombophilia and associated risk of VTE during pregnancy (from Task Force Haemostasis and Thrombosis, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. *Br J Haematol* 2001;114:512-28., da Robertson L, Wu O, Langhorne P, et al. Thrombophilia in pregnancy: a systematic review. *Br J Haematol* 2006;132:171-96., da Nelson SM, Greer IA. Thrombophilia and the risk for venous thromboembolism during pregnancy, delivery, and puerperium. *Obstet Gynecol Clin North Am* 2006;33:413-27).

For the assessment of ante and postpartum VTE risk and thromboprophylaxis, refer to Figures 4 and 5.

Thromboprophylaxis during labor and safety of epidural/peridural blocks.


Women receiving LMWH in the prenatal period should be informed that if vaginal bleeding occurs or spontaneous labor begins, they should not inject additional LMWH. Peridural block is a validated primary thromboprophylactic method, although not self-sufficient. Furthermore, compared to general anesthesia, this method has demonstrated advantages in terms of reducing maternal mortality and improving perinatal outcomes.

The peridural block should be performed at least 12 hours after the prophylactic LMWH dose. Peridural techniques should be avoided in patients who have received LMWH 2 hours prior, as the puncture would be performed during the peak activity of anticoagulants.


Patients who are candidates for postoperative thromboprophylaxis with LMWH can undergo spinal techniques. Postoperative thromboprophylaxis following cesarean section is compatible with the maintenance of an epidural catheter as long as it is well secured to prevent accidental displacement.

Strict adherence to the time intervals for administering LMWH doses is required:

- The first prophylactic LMWH dose can be administered 12 hours after the central block, and subsequent doses should follow the protocol at 24-hour intervals.
- At least 6 hours should elapse after the removal of the epidural catheter before administering a dose of LMWH.
- The removal of the peridural catheter should be deferred for at least 10-12 hours after a dose of LMWH.



**Figure 4:** Risk factors for VTE in pregnancy and thromboprophylaxis in the prenatal period (from Nelson-Piercy C, MacCallum P, Mackillop L. Green-top Guideline No. 37a:Reducing the risk of venous thromboembolism during pregnancy and the puerperium. London, Royal College of Obstetricians and Gynaecologists, 2015).



**Figure 5:** Risk factors for VTE in pregnancy and thromboprophylaxis in the postnatal period (from Nelson-Piercy C, MacCallum P, Mackillop L. Green-top Guideline No. 37a-Reducing the risk of venous thromboembolism during pregnancy and the puerperium London, Royal College of Obstetricians and Gynecologists, 2015).

**APPENDIX 2: Low Molecular Weight Heparin: Label or Off-Label Use?**

**LAW 648/96**

The prescription of LMWH in FILE F is allowed only for SECONDARY PROPHYLAXIS, not for primary prophylaxis!

The inclusion criteria from the AIFA (Italian Medicines Agency) Determination of July 20, 2016, are:

1. Previous idiopathic venous thromboembolic event or ongoing treatment with estrogen-progestin agents, regardless of the presence of thrombophilia (prophylaxis);
2. Recurrent unexplained miscarriages (defined as a number  $\geq 3$ , or 2 in the presence of at least one normal fetal karyotype) with documented congenital or acquired thrombophilia (prophylaxis);
3. One or more intrauterine fetal deaths (IUFD), defined as fetal loss occurring from the 20th week of gestation onwards in a morphologically normal fetus (prophylaxis);

4. Previous severe pre-eclampsia, intrauterine growth restriction, and placental abruption with normally inserted placenta "sine causa" (prophylaxis);
5. Mechanical heart valves: from pregnancy confirmation until the end of the first trimester (approximately 10-14 weeks) and from the 34th week until delivery. From the 14<sup>th</sup> to the 34<sup>th</sup> week based on clinical judgment and after shared decision-making with the patient (treatment).

**Exclusion criteria:**

1. Fetal aneuploidy in previous pregnancies;
2. Fetal malformations and/or aneuploidy in the current pregnancy;
3. Abnormal parental karyotype;
4. Thrombocytopenia (<50,000/microliter);
5. Known bleeding disorders;
6. Allergy to LMWH.

**Copyright:** ©2023 Salvatore Felis, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are credited.